Orchid Pharma Limited (ORCHPHARMA) AI Stock Analysis

• Market Cap: ₹36.53B
• Dividend Yield: N/A
• Average Volume (3M): 10.21K
• Price to Earnings (P/E): 42.9
• Beta (1Y): 1.45
• Revenue Growth: -3.45%
• EPS Growth: -23.60%
• Country: IN
• Employees: 871
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.90
• Shares Outstanding: 50,719,105
• 10 Day Avg. Volume: 2,303
• 30 Day Avg. Volume: 10,213
• PEG Ratio: 12.87
• Price to Book (P/B): 3.13
• Price to Sales (P/S): 4.31
• P/FCF Ratio: -30.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ₹774.00 ▲(9.14% Upside)

Orchid Pharma's overall stock score is driven by strong financial performance, particularly in revenue growth and profitability. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates overvaluation. The lack of dividend yield further impacts the valuation score.

Orchid Pharma Limited Business Overview & Revenue Model

Company Description

Orchid Pharma Limited (ORCHPHARMA) is a pharmaceutical company based in India, primarily focused on the development, manufacturing, and marketing of generic and specialty pharmaceutical products. The company operates in various therapeutic segments, including anti-infectives, cardiovascular, and central nervous system disorders. With a strong emphasis on research and development, Orchid Pharma has established a diverse portfolio of products that cater to both domestic and international markets.

How the Company Makes Money

Orchid Pharma generates revenue through several key streams, including the sale of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and specialty formulations. The company leverages its manufacturing capabilities to produce high-quality generics that are marketed both in India and abroad, particularly in regulated markets such as the United States and Europe. Additionally, Orchid Pharma engages in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product offerings and market reach. The firm's focus on research and development allows it to innovate and expand its product pipeline, contributing to ongoing revenue growth.

Orchid Pharma Limited Financial Statement Overview

Summary

Orchid Pharma shows strong revenue growth and a healthy gross profit margin. The balance sheet is robust with low leverage, but cash flow challenges, including negative free cash flow, need addressing. Operational efficiency improvements are necessary.

Income Statement

Orchid Pharma has demonstrated strong revenue growth, with a 12.54% increase in the last year. The gross profit margin is healthy at 40.97%, and the company has managed to turn around its net income from previous losses to a net profit margin of 10.81%. However, the EBIT margin of 27.85% and EBITDA margin of 15.69% indicate room for improvement in operational efficiency.

Balance Sheet

The company's balance sheet is robust, with an equity ratio of 75.08% suggesting strong financial stability. The debt-to-equity ratio is low at 0.14, indicating low leverage. The return on equity (ROE) is 7.86%, which, while positive, indicates moderate return generation from equity.

Cash Flow

Cash flow analysis shows potential stress, with a substantial decline in free cash flow from last year. The operating cash flow to net income ratio of 0.19 suggests low conversion of income into cash. Free cash flow has turned negative, which could pose challenges for future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.50B	9.22B	8.19B	6.66B	5.60B	4.50B
Gross Profit	3.58B	3.55B	1.36B	706.89M	2.32B	2.09B
EBITDA	1.30B	1.45B	1.42B	1.43B	635.82M	658.74M
Net Income	852.17M	996.57M	921.66M	463.18M	-19.51M	-1.17B
Balance Sheet
Total Assets	0.00	16.88B	15.54B	12.25B	11.11B	12.37B
Cash, Cash Equivalents and Short-Term Investments	1.80B	1.83B	45.24M	275.21M	48.27M	315.15M
Total Debt	0.00	1.75B	1.35B	3.31B	2.68B	4.53B
Total Liabilities	-12.67B	4.21B	3.84B	5.37B	4.63B	5.84B
Stockholders Equity	12.67B	12.67B	11.69B	6.89B	6.47B	6.53B
Cash Flow
Free Cash Flow	0.00	-1.31B	611.77M	-665.75M	780.71M	229.82M
Operating Cash Flow	0.00	192.15M	1.26B	183.38M	924.75M	235.86M
Investing Cash Flow	0.00	-269.31M	-3.12B	-312.14M	1.13B	672.05M
Financing Cash Flow	0.00	252.22M	1.67B	311.66M	-2.17B	-1.65B

Orchid Pharma Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 709.20
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ORCHPHARMA, the sentiment is Negative. The current price of 709.2 is below the 20-day moving average (MA) of 725.33, below the 50-day MA of 731.67, and below the 200-day MA of 855.95, indicating a bearish trend. The MACD of -5.50 indicates Positive momentum. The RSI at 43.54 is Neutral, neither overbought nor oversold. The STOCH value of 21.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ORCHPHARMA.

Orchid Pharma Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADVENZYMES	―	₹34.85B	25.58	―	1.69%	5.89%	-1.30%
MOREPENLAB	―	₹26.44B	28.56	―	0.41%	2.12%	-25.99%
ORCHPHARMA	―	₹36.53B	42.87	―	―	-3.45%	-23.60%
GUFICBIO	―	₹35.26B	57.00	―	0.03%	2.37%	-30.78%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Orchid Pharma Limited Corporate Events

Orchid Pharma’s 32nd AGM: Virtual Meeting and Voting Results Announced

Orchid Pharma Limited announced the results of its 32nd Annual General Meeting, which was held virtually on September 20, 2025. The meeting, conducted in compliance with regulatory guidelines, included remote e-voting and e-voting at the AGM. This approach reflects the company’s adaptation to ongoing pandemic-related challenges, ensuring shareholder participation and compliance with corporate governance standards.